Stock·NYSE·Healthcare
Eli Lilly and Company (LLY)
- Market cap
- $1.12T
- P/E
- 42.01
- Dividend yield
- 0.53%
- Street target
- $1,385.00median of 30 analysts
- 52-week range
- $793.82 $1,292.65
The short version
Where LLY stands today, in four lines, and what CleaRank Financial AI makes of it.
LLY at a glance
Eli Lilly and Company (LLY): Buy, 78/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($1,180.35 and $1,079.91).
- Earnings LLY beat estimates in 6 of its last 7 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $3.9B and bought $4.5M over the last 18 months.
- Valuation P/E of 42.0 against 31.9 for the Healthcare sector: a premium to peers (+32%).
Figures as of October 17, 2026.
CleaRank Financial AI
Eli Lilly and Company (LLY) receives a CleaRank rating of Buy and a model score of 78/100.
Trend is the strongest contributor: the price is 16.40% above its 200-day average and 6.50% above its 50-day average, and the 50-day average is 9.30% above the 200-day. Valuation is the largest drag, with the P/E of 42.01 31.7% above the sector median (a premium to peers) and the P/S of 14.00 311.8% above the sector median. The 50-day average is $1,180.35 and the 200-day is $1,079.91, and over the past year the price has risen 53.41%.
Only on CleaRank
Figures we compute ourselves from LLY's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $1,257.03 is 6.5% above the 50-day simple moving average of $1,180.35.Price above its 200-day average ›
The price is 16.4% above the 200-day simple moving average of $1,079.91.50-day average above the 200-day ›
The 50-day average ($1,180.35) is 9.3% above the 200-day average ($1,079.91), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 93% of its 52-week range, between $793.82 and $1,292.65.
LLY share price
Pick a period: each tab shows how far LLY has moved over it, to the last close.
Today's trading
Where LLY sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 42.01 is 31.7% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 14.00 is 311.9% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $26.7B on revenue of $79.7B, a net margin of 33.5%.Beat estimates in most recent reports ›
LLY beat the EPS estimate in 6 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 0.53%, or $6.69 a share a year.
Key statistics
The headline figures for LLY.
As of October 17, 2026, LLY trades at $1,257.03, with a market value of $1.12T, a P/E ratio of 42.01 and a dividend yield of 0.53%.
What the numbers say
CleaRank Financial AI's reading of LLY's valuation, growth and risks.
Eli Lilly and Company (LLY) has a trailing P/E of 42.01, which is 31.7% above the Healthcare median of 31.9. The peer comparison on this page rates that as a premium to peers. Measured against sales, the P/S of 14.00 is 311.8% above the sector median of 3.4. LLY has a market value of $1.12T.
In the latest year revenue grew 47.70%, 39.6 percentage points faster than the sector median of 8.1%. The business earns a net margin of 33.53% and an operating margin of 54.22% and a return on equity of 102.29%, above the sector median of 7.3%. Debt-to-equity of 1.62 and a trailing dividend yield of 0.53% ($6.69 a share a year) round out the fundamentals.
LLY beat expectations in the August 5, 2026 report by 27.36%, with EPS of $8.38 against an estimate of $6.58. In the first session after the report, the share price rose 1.89%.
Over its last 8 reports, LLY topped the estimate 6 times, but beats have not guaranteed gains: the stock fell the next day after 2 of them. Earlier, the stock fell 7.79% after the February 4, 2026 report, a beat of 9.12%. Analysts' average EPS estimate for this fiscal year is $36.77, which would be growth of 51.9%, and $47.60 for next year (growth of 29.5%).
Valuation leaves less margin for error: the P/E of 42.01 is 31.7% above the sector median, a premium to peers. Normal swings for LLY run at about 1.50% a day.
LLY against the Healthcare sector
How LLY compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: LLY trades at a significant premium to sector peers (+32%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 6, 2025, LLY has gained 62.2% against a gain of 31.4% for XLV.
Performance against XLV
LLY and the Healthcare sector fund over the same days.
Revenue and earnings
How much LLY sells, and how much of it becomes profit.
Revenue growth: Revenue grew 44.7% in FY2025 to $65.2B, from $45.0B a year earlier.
Profit margin: The net margin was 31.7% in FY2025, up from 23.5% the year before.
Profitable: LLY earned $20.6B in FY2025.
Earnings reality check
Did LLY beat what analysts expected, and how did the stock react?
Earnings record: LLY beat the analyst estimate in 6 of the last 7 quarters.
Market reaction: The stock fell in the first session after 2 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | $6.58 | $8.38 | +27.36% | +1.89% | +4.31% |
| Apr 30, 2026after close | $6.79 | $8.55 | +25.92% | +3.07% | +4.32% |
| Feb 4, 2026after close | $6.91 | $7.54 | +9.12% | -7.79% | -8.30% |
| Oct 30, 2025after close | $5.89 | $7.02 | +19.19% | +2.17% | +11.01% |
| Aug 7, 2025after close | $5.59 | $6.31 | +12.88% | -2.37% | +6.80% |
| May 1, 2025after close | $3.46 | $3.34 | -3.47% | +3.72% | -5.37% |
| Feb 6, 2025after close | $5.07 | $5.32 | +4.93% | +0.91% | +0.17% |
As of October 17, 2026, LLY has beaten the analyst EPS estimate in 6 of its last 7 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on August 5, 2026, came in 27.36% above the estimate and the stock moved +1.89% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 68.6, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 68.6 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of LLY
The score, the reasoning behind it, and what could move the price next.
The price of $1,257.03 sits above both moving averages, a pattern that usually marks an uptrend. It is 6.50% above the 50-day average of $1,180.35 and 16.40% above the 200-day average of $1,079.91. The price is at 93% of its 52-week range, and 2.76% below the 52-week high of $1,292.65. Meanwhile the 50-day average is 9.30% above the 200-day average.
On momentum, the 14-day RSI reads 68.6, in the bullish zone, below the overbought line, with the MACD line positive. Every period on the chart shows a gain, with the price up 6.61% over the past three months, 35.60% over the past six months and 53.41% over the past year.
Earnings beat ›
The August 5, 2026 report beat the EPS estimate by 27.36%, and the share price rose 1.89% in the first session after it.
Source: Earnings report, August 5, 2026
Rating reaffirmed ›
Cantor Fitzgerald kept its Overweight rating on October 8, 2026.
Source: Analyst action, Cantor Fitzgerald, October 8, 2026
- The two levels to track are the 52-week high at $1,292.65, which sits above the price, and the 20-day EMA at $1,185.80, which sits below it.
- The 14-day RSI reads 68.6, in the bullish zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- The share price rose 1.89% in the first session after the August 5, 2026 report. Over the last 8 reports, LLY has beaten estimates in 6 of them.
LLY trades above its 50-day and 200-day moving averages ($1,180.35 and $1,079.91), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 20-day EMA at $1,185.80.
The next level above the price is the 52-week high at $1,292.65. The RSI is in the bullish band, which supports the current direction, though it sits close to the overbought line.
Technical indicators
Momentum and trend for LLY, from its daily closes.
As of October 17, 2026, with LLY at $1,257.03, its 14-day RSI is 68.6 (showing bullish momentum without being overbought), its 50-day simple moving average is $1,180.35 and its 200-day is $1,079.91.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What LLY moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, LLY's 1-year correlation of daily returns is +0.24 with S&P 500 (SPY), +0.15 with Nasdaq 100 (QQQ), +0.10 with Bitcoin (BTC) and +0.13 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
25 of 30 analysts rate it a buy or strong buy, 3 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $1,385.00 is 10.2% above the price.More buy ratings than three months ago ›
25 of 30 rate it a buy now, against 22 of 28 three months ago.
LLY Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | Cantor Fitzgerald | Maintains | Overweight |
| Oct 7, 2026 | Morgan Stanley | Maintains | Overweight |
| Sep 28, 2026 | JP Morgan | Maintains | Overweight |
| Sep 22, 2026 | TD Cowen | Reiterates | Buy |
| Sep 18, 2026 | Guggenheim | Maintains | Buy |
| Sep 10, 2026 | HSBC | Maintains | Reduce |
As of October 17, 2026, 30 Wall Street analysts cover LLY: 25 rate it a buy or strong buy, 3 a hold and 2 a sell or strong sell. Their 12-month price targets range from $930.00 to $1,600.00, with a median of $1,385.00, 10.2% above the price of $1,257.03.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
LLY trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from LLY's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much LLY tends to move, against the market and on its own.
The long record
LLY's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.50% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 33.5%, from August 2024 to August 2025, regained by November 2025.Most 1-year holds ended higher ›
92% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $187,046, against $42,055 in the S&P 500 (SPY).
LLY Drawdowns & Recovery
As of October 17, 2026, LLY's worst peak-to-trough fall over the last 10 years with dividends reinvested was -33.5% (August 2024 to August 2025); it regained that peak by November 2025, 3 months after the low, and 92% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into LLY in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: LLY beat the S&P 500 over this period: $187,046 against $42,055.
A $10,000 investment in LLY in October 2016 would be worth about $187,046 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to LLY, and which have not.
Strongest month, June: an average of +7.12%, up in 9 of 10 years.
Weakest month, September: an average of -0.77%, up in 5 of 10 years.
This month, October: has averaged +3.40%, up in 7 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, LLY's strongest calendar month has been June (average +7.12%, up in 9 of 10 years) and its weakest September (average -0.77%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in LLY, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in LLY today could grow to about $29,545 by 2036 in the base case, with a 90th-percentile outcome near $101,380 and a 10th-percentile outcome around $8,610. The simulation models price only; at today's 0.53% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
LLY Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $1,939 for LLY by 2030 in the base case, from $1,257 today (1.5x over 4 years). The 10th-percentile path ends near $889. These are outcomes of a Monte Carlo simulation run on LLY's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $949 | $1,401 | $2,069 | |
| 2028 | $899 | $1,561 | $2,710 | |
| 2029 | $886 | $1,740 | $3,418 | |
| 2030 | $889 | $1,939 | $4,229 | |
| 2031 | $904 | $2,161 | $5,167 |
Method: a lognormal simulation of LLY's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
LLY insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $4.5M on the open market and sold $3.9B.
As of October 17, 2026, LLY insiders reported 46 open-market sales worth $3.9B and 8 open-market purchases worth $4.5M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 21, 2026 | Ralph Alvarez
Director
|
Grant | 10 | $12.4K |
| Sep 21, 2026 | J. Erik Fyrwald
Director
|
Grant | 8 | $9.9K |
| Sep 21, 2026 | Juan R Luciano
Director
|
Grant | 13 | $15.9K |
| Sep 21, 2026 | Gabrielle Sulzberger
Director
|
Grant | 4 | $5.0K |
| Sep 9, 2026 | Melissa Seymour
Officer
|
Grant | 29 | - |
| Sep 2, 2026 | Eric Dozier
Officer
|
Grant | 216 | - |
| Sep 2, 2026 | Edgardo Hernandez
Officer
|
Grant | 13 | - |
| Aug 17, 2026 | Patrik Jonsson
Officer
|
Sell | 6.5K | $7.6M |
| Aug 17, 2026 | Ralph Alvarez
Director
|
Grant | 10 | $12.4K |
| Aug 17, 2026 | J. Erik Fyrwald
Director
|
Grant | 8 | $9.9K |
| Aug 17, 2026 | Juan R Luciano
Director
|
Grant | 13 | $15.9K |
| Aug 17, 2026 | Gabrielle Sulzberger
Director
|
Grant | 4 | $5.0K |
| Aug 10, 2026 | Donald A Zakrowski
Officer
|
Sell | 2.0K | $2.4M |
| Aug 7, 2026 | Anat Hakim
General Counsel
|
Sell | 5.0K | $6.0M |
| Jul 31, 2026 | Melissa Seymour
Officer
|
Grant | 981 | - |
| Jul 20, 2026 | Ralph Alvarez
Director
|
Grant | 10 | $12.4K |
| Jul 20, 2026 | J. Erik Fyrwald
Director
|
Grant | 8 | $9.9K |
| Jul 20, 2026 | Juan R Luciano
Director
|
Grant | 13 | $15.9K |
| Jul 20, 2026 | Gabrielle Sulzberger
Director
|
Grant | 4 | $5.0K |
| Jun 15, 2026 | Ralph Alvarez
Director
|
Grant | 10 | $12.4K |
| Jun 15, 2026 | J. Erik Fyrwald
Director
|
Grant | 8 | $9.9K |
| Jun 15, 2026 | Juan R Luciano
Director
|
Grant | 14 | $15.9K |
| Jun 15, 2026 | Gabrielle Sulzberger
Director
|
Grant | 4 | $5.0K |
| Jun 10, 2026 | Ilya Yuffa
Officer
|
Sell | 2.5K | $2.9M |
| May 18, 2026 | Ralph Alvarez
Director
|
Grant | 12 | $12.4K |
| May 18, 2026 | J. Erik Fyrwald
Director
|
Grant | 10 | $9.9K |
| May 18, 2026 | Juan R Luciano
Director
|
Grant | 16 | $15.9K |
| May 18, 2026 | Gabrielle Sulzberger
Director
|
Grant | 5 | $5.0K |
| May 6, 2026 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 15.8K | $15.8M |
| Apr 20, 2026 | Ralph Alvarez
Director
|
Grant | 13 | $12.4K |
| Apr 20, 2026 | J. Erik Fyrwald
Director
|
Grant | 10 | $9.9K |
| Apr 20, 2026 | Juan R Luciano
Director
|
Grant | 17 | $15.9K |
| Apr 20, 2026 | Gabrielle Sulzberger
Director
|
Grant | 5 | $5.0K |
| Mar 16, 2026 | Ralph Alvarez
Director
|
Grant | 12 | $12.4K |
| Mar 16, 2026 | J. Erik Fyrwald
Director
|
Grant | 10 | $9.9K |
| Mar 16, 2026 | Juan R Luciano
Director
|
Grant | 16 | $15.9K |
| Mar 16, 2026 | Gabrielle Sulzberger
Director
|
Grant | 5 | $5.0K |
| Feb 19, 2026 | Eric Dozier
Officer
|
Grant | 481 | - |
| Feb 17, 2026 | Ralph Alvarez
Director
|
Grant | 11 | $12.4K |
| Feb 17, 2026 | J. Erik Fyrwald
Director
|
Grant | 9 | $9.9K |
| Feb 17, 2026 | Juan R Luciano
Director
|
Grant | 15 | $15.9K |
| Feb 17, 2026 | Gabrielle Sulzberger
Director
|
Grant | 4 | $5.0K |
| Feb 13, 2026 | Adriane S Brown
Officer
|
Grant | 391 | - |
| Feb 13, 2026 | Kenneth L Custer
Officer
|
Grant | 207 | - |
| Feb 13, 2026 | Lucas E Montarce
Chief Financial Officer
|
Grant | 368 | - |
| Feb 13, 2026 | Donald A Zakrowski
Chief Financial Officer
|
Grant | 184 | - |
| Feb 9, 2026 | Adriane S Brown
Officer
|
Grant | 1.2K | $1.2M |
| Feb 9, 2026 | Kenneth L Custer
Officer
|
Grant | 659 | $688.7K |
| Feb 9, 2026 | Eric Dozier
Officer
|
Grant | 3.5K | $3.7M |
| Feb 9, 2026 | Anat Hakim
General Counsel
|
Grant | 8.3K | $8.6M |
| Feb 9, 2026 | Edgardo Hernandez
Officer
|
Grant | 4.4K | $4.6M |
| Feb 9, 2026 | Patrik Jonsson
Officer
|
Grant | 4.8K | $5.0M |
| Feb 9, 2026 | Lucas E Montarce
Chief Financial Officer
|
Grant | 1.4K | $1.4M |
| Feb 9, 2026 | Diogo Rau
Chief Technology Officer
|
Grant | 4.4K | $4.6M |
| Feb 9, 2026 | Diogo Rau
Officer
|
Grant | 4.6K | $4.8M |
| Feb 9, 2026 | David A Ricks
Chief Executive Officer
|
Grant | 38.9K | $40.7M |
| Feb 9, 2026 | Daniel Skovronsky
Officer
|
Grant | 15.5K | $16.2M |
| Feb 9, 2026 | Naarden Jacob S. Van
Officer
|
Grant | 4.9K | $5.1M |
| Feb 9, 2026 | Ilya Yuffa
Officer
|
Grant | 4.2K | $4.3M |
| Feb 9, 2026 | Donald A Zakrowski
Officer
|
Grant | 583 | $609.9K |
| Jan 30, 2026 | Eric Dozier
Officer
|
Grant | 2.9K | - |
| Jan 30, 2026 | Anat Hakim
General Counsel
|
Grant | 6.7K | - |
| Jan 30, 2026 | Edgardo Hernandez
Officer
|
Grant | 3.6K | - |
| Jan 30, 2026 | Patrik Jonsson
Officer
|
Grant | 3.9K | - |
| Jan 30, 2026 | Diogo Rau
Officer
|
Grant | 3.8K | - |
| Jan 30, 2026 | David A Ricks
Chief Executive Officer
|
Grant | 31.9K | - |
| Jan 30, 2026 | Daniel Skovronsky
Officer
|
Grant | 12.7K | - |
| Jan 30, 2026 | Naarden Jacob S. Van
Officer
|
Grant | 4.1K | - |
| Jan 30, 2026 | Ilya Yuffa
Officer
|
Grant | 3.4K | - |
| Jan 20, 2026 | Ralph Alvarez
Director
|
Grant | 11 | $12.4K |
| Jan 20, 2026 | J. Erik Fyrwald
Director
|
Grant | 9 | $9.9K |
| Jan 20, 2026 | Juan R Luciano
Director
|
Grant | 15 | $15.9K |
| Jan 20, 2026 | Gabrielle Sulzberger
Director
|
Grant | 4 | $5.0K |
| Jan 7, 2026 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 292.1K | $322.4M |
| Jan 5, 2026 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 1.4K | $1.5M |
| Dec 29, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 3.6K | $3.9M |
| Dec 24, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 2.6K | $2.9M |
| Dec 23, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 240 | $260.4K |
| Dec 15, 2025 | Ralph Alvarez
Director
|
Grant | 11 | $11.8K |
| Dec 15, 2025 | J. Erik Fyrwald
Director
|
Grant | 9 | $9.9K |
| Dec 15, 2025 | Mary Lynne Hedley
Director
|
Grant | 9 | $9.9K |
| Dec 15, 2025 | Juan R Luciano
Director
|
Grant | 13 | $14.8K |
| Dec 15, 2025 | Gabrielle Sulzberger
Director
|
Grant | 4 | $5.0K |
| Nov 25, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 147.1K | $161.1M |
| Nov 25, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 15.6K | $17.3M |
| Nov 24, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 142.3K | $152.1M |
| Nov 21, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 105.3K | $111.5M |
| Nov 20, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 37.1K | $39.1M |
| Nov 19, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 167.5K | $176.1M |
| Nov 18, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 60.2K | $62.3M |
| Nov 17, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 9.9K | $10.2M |
| Nov 17, 2025 | Katherine Baicker
Director
|
Grant | 215 | $220.0K |
| Nov 17, 2025 | J. Erik Fyrwald
Director
|
Grant | 225 | $229.9K |
| Nov 17, 2025 | Mary Lynne Hedley
Director
|
Grant | 225 | $229.9K |
| Nov 17, 2025 | Jamere Jackson
Director
|
Grant | 215 | $220.0K |
| Nov 17, 2025 | Kimberly H Johnson
Director
|
Grant | 215 | $220.0K |
| Nov 17, 2025 | William G Kaelin Jr
Director
|
Grant | 215 | $220.0K |
| Nov 17, 2025 | Jon R Moeller
Director
|
Grant | 233 | $238.3K |
| Nov 17, 2025 | Gabrielle Sulzberger
Director
|
Grant | 220 | $225.0K |
| Nov 14, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 178.3K | $183.3M |
| Nov 13, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 46.6K | $48.0M |
| Nov 13, 2025 | Donald A Zakrowski
Officer
|
Sell | 1.0K | $1.0M |
| Nov 12, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 305.0K | $308.4M |
| Nov 11, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 283.1K | $279.3M |
| Nov 10, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 16.9K | $16.4M |
| Nov 10, 2025 | David A Ricks
Chief Executive Officer
|
Grant | 24.8K | - |
| Nov 10, 2025 | Daniel Skovronsky
Officer
|
Grant | 179 | - |
| Nov 5, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 179.0K | $167.1M |
| Nov 5, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 40.4K | $38.5M |
| Nov 4, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 526 | $479.0K |
| Nov 3, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 300.0K | $266.6M |
| Oct 31, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 301.3K | $260.2M |
| Oct 20, 2025 | Ralph Alvarez
Director
|
Grant | 14 | $11.8K |
| Oct 20, 2025 | J. Erik Fyrwald
Director
|
Grant | 12 | $9.9K |
| Oct 20, 2025 | Juan R Luciano
Director
|
Grant | 18 | $14.8K |
| Oct 20, 2025 | Gabrielle Sulzberger
Director
|
Grant | 6 | $5.0K |
| Oct 10, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 3.7K | $3.2M |
| Oct 9, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 10.6K | $9.0M |
| Oct 8, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 101.4K | $86.2M |
| Oct 7, 2025 | Lilly Endowment, Inc.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 26.8K | $22.7M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.